title: Role of procoagulant lipids in human prothrombin activation. 1. Prothrombin activation by factor X(a) in the absence of factor V(a) and in the absence and presence of membranes.
abstract: Activation of prothrombin by factor X(a) requires proteolysis of two bonds and is commonly assumed to occur via by two parallel, sequential pathways. Hydrolysis of Arg(322)-Ile(323) produces meizothrombin (MzII(a)) as an intermediate, while hydrolysis of Arg(273)-Thr(274) produces prethrombin 2-fragment 1.2 (Pre2-F1.2). Activation by human factor X(a) of human prothrombin was examined in the absence of factor V(a) and in the absence and presence of bovine phosphatidylserine (PS)/palmitoyloleoylphosphatidylcholine (25:75) membranes. Four sets of data were collected: fluorescence of an active site probe (DAPA) was sensitive to thrombin, MzII(a), and Pre2-F1.2; a synthetic substrate (S-2238) detected thrombin or MzII(a) active site formation; and SDS-PAGE detected both intermediates and thrombin. The fluorescence data provided an internal check on the active site and SDS-PAGE measurements. Kinetic constants for conversion of intermediates to thrombin were measured directly in the absence of membranes. Both MzII(a) and Pre2-F1.2 were consumed rapidly in the presence of membranes, so kinetic constants for these reactions had to be estimated as adjustable parameters by fitting three data sets (thrombin and MzII(a) active site formation and Pre2 appearance) simultaneously to the parallel-sequential model. In the absence of membranes, this model successfully described the data and yielded a rate constant, 44 M(-1) s(-1), for the rate of MzII(a) formation. By contrast, the parallel-sequential model could not describe prothrombin activation in the presence of optimal concentrations of PS-containing membranes without assuming that a pathway existed for converting prothrombin directly to thrombin without release from the membrane-enzyme complex. The data suggest that PS membranes (1) regulate factor X(a), (2) alter the substrate specificity of factor X(a) to favor the meizothrombin intermediate, and (3) "channel" intermediate (MzII(a) or Pre2-F1.2) back to the active site of factor X(a) for rapid conversion to thrombin.
authors.affiliation: Department of Biochemistry and Biophysics, CB 7260, University of North Carolina at Chapel Hill, 27599-7260, USA.
authors.forename: Jogin R
authors.initials: JR
authors.lastname: Wu
authors.forename: Chaoming
authors.initials: C
authors.lastname: Zhou
authors.forename: Rinku
authors.initials: R
authors.lastname: Majumder
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Powers
authors.forename: Gabriel
authors.initials: G
authors.lastname: Weinreb
authors.forename: Barry R
authors.initials: BR
authors.lastname: Lentz
mesh_terms: D000818:Animals; D001665:Binding Sites; D002417:Cattle; D004789:Enzyme Activation; D015943:Factor Va / Q000378:metabolism*; D015951:Factor Xa / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008081:Liposomes; D010713:Phosphatidylcholines / Q000494:pharmacology; D010718:Phosphatidylserines / Q000494:pharmacology; D011516:Prothrombin / Q000378:metabolism*; D013917:Thrombin / Q000737:chemistry / Q000378:metabolism
chemical_list: D008081:Liposomes; D010713:Phosphatidylcholines; D010718:Phosphatidylserines; D015943:Factor Va; D011516:Prothrombin; D013917:Thrombin; D015951:Factor Xa; C028694:1-palmitoyl-2-oleoylphosphatidylcholine